The economic burden of disease-related undernutrition in selected chronic diseases

Benković, Vanesa; Kolčić, Ivana; Uhernik, Ana Ivičević; Bender, Darija Vranešić; Oreb, Ida; Stevanović, Ranko; Krznarić, Željko

doi:10.1016/j.clnu.2013.09.006

Cited by 19 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, malnutrition among hospitalized patients is a far from trivial condition, leading to a considerable health and economic burden. Moreover, the reported costs are likely to be an underestimate as not all increased treatment costs were included [24].…”

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 97%

“…Except one study conducted in a Gastroenterology Ward [7] all the others were multidisciplinary [6,7,10,13,15,18,23e25]. For nutritional status, one study used the NRI [15], one the SGA [7], four the NRS-2002 [6,13,18,24], two the Malnutrition Universal Screening Tool (MUST) [23,25] and one used Body Mass Index (BMI) and weight loss [10]. Most malnutrition rates ranged from 19 [7] to 44% [10], with the exception of the Croatian study, which reported a much lower prevalence (3.37%) [24].…”

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 98%

“…In the Netherlands, the total additional costs (prevention, diagnostic, therapy, rehabilitation and care of the disease or treatment under consideration) of DRM were estimated at 1.9 billion V (2.1% of the national health expenditure), of which 1.2 billion V (66%) were attributed to hospital settings [10]. In Croatia, the total direct costs of malnourished patients were estimated at 97.35 million V (3.38% of the national health care budget), of which 32.8 million V (34%) were attributed to hospital malnutrition, leading to an average cost of malnutrition of 1640.48 V per hospitalized patient [24].…”

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

“…For nutritional status, one study used the NRI [15], one the SGA [7], four the NRS-2002 [6,13,18,24], two the Malnutrition Universal Screening Tool (MUST) [23,25] and one used Body Mass Index (BMI) and weight loss [10]. Most malnutrition rates ranged from 19 [7] to 44% [10], with the exception of the Croatian study, which reported a much lower prevalence (3.37%) [24]. One paper had data on costs according to malnutrition status, but it was unclear which definition was applied, so it was not included; total costs were 1912 V (no standard deviation provided) for well nourished and 2990 V for malnourished patients [19].…”

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

“…Malnutrition led to an additional increase in costs among hospitalized patients ranging between 1640 [24] and 5829 V [13] per patient. Taken together, malnutrition-related costs represented between 2.1 and 10% of the national health expenditure.…”

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

See 4 more Smart Citations

The economic cost of hospital malnutrition in Europe; a narrative review

Khalatbari-Soltani

Marques‐Vidal

2015

Clinical Nutrition ESPEN

View full text Add to dashboard Cite

show abstract

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 97%

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 98%

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

Section: Impact Of Malnutrition On Hospital Costsmentioning

confidence: 99%

See 3 more Smart Citations

The economic cost of hospital malnutrition in Europe; a narrative review

Khalatbari-Soltani

Marques‐Vidal

2015

Clinical Nutrition ESPEN

View full text Add to dashboard Cite

show abstract

A systematic review of the malnutrition prevalence in hospitalized hip fracture patients and its associated outcomes

Foo

Wong

Lew

2021

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background Malnutrition is associated with poorer outcomes in hospitalized patients. However, in hip fracture patients, the associations between malnutrition and poorer outcomes are unclear because of the use of nonestablished nutrition assessment tools in previous studies that may have some degree of misclassification bias. Therefore, this review aims to determine (1) the prevalence of malnutrition diagnosed in hospitalized hip fracture patients using established nutrition assessment tools and (2) the outcomes associated with malnutrition given some of the nonestablished nutrition assessment tools used in previous studies. Methods Four electronic databases were used. Studies that used established nutrition assessment tools to diagnose malnutrition in hip fracture patients within 48 h of hospital admission were included. Results Nine studies were included (n = 1665). Patients’ mean age ranged from 79.9 to 86.1 years. Eight studies reported the frequencies of each sex, and for females, it ranged from 70% to 81.8%. The prevalence of malnutrition was 4.0% to 39.4%. Malnutrition was independently associated with (1) increased mortality and (2) functional dependence. There was also a trend towards more supported living arrangements and impaired mobility in the longer term. Malnutrition was not associated with (1) hospital length of stay, (2) hospital readmissions, and (3) incidence of complications. Conclusion The prevalence of malnutrition in hip fracture patients is highly variable and is associated with poorer outcomes. Therefore, identifying malnourished hip fracture patients using established nutrition assessment tools is important, and adequate resources can be allocated to prevent malnutrition through early screening and intervention.

show abstract

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Neff

Zachry²

2018

PharmacoEconomics

View full text Add to dashboard Cite

BackgroundHepatic encephalopathy (HE), a common neurologic complication in cirrhosis, is associated with substantial disease and economic burden. Rifaximin is a non-systemic antibiotic that reduces the risk of overt HE recurrence and overt HE-related hospitalizations.ObjectiveOur objective was to provide an overview of the direct HE-related costs and cost benefits of rifaximin, lactulose, and rifaximin plus lactulose.MethodsA systematic review of PubMed and relevant meeting abstracts was conducted to identify publications since 1 January 2007 reporting economic data related to HE and rifaximin and/or lactulose. Further, a public database and published literature were used to estimate current costs of hospitalization for overt HE, and potential cost savings of HE-related hospitalizations with rifaximin. The methodological quality of included studies was evaluated using the Drummond checklist.ResultsA total of 16 reports were identified for inclusion in the systematic review. Globally, HE-related direct costs ranged from $US5370 to $US50,120 annually per patient. Rifaximin was associated with shorter hospital stays and reduced healthcare costs. Rifaximin also has the potential to reduce overt HE-related hospitalization risk by 50% compared with lactulose. Rifaximin was shown to have a favourable pharmacoeconomic profile compared with lactulose (based on the incremental cost-effectiveness ratio).ConclusionsIn addition to its clinical benefits (e.g. reduction in the risk of recurrence of overt HE, overt HE-related hospitalizations, favourable adverse event profile), economic data are favourable for the use of rifaximin in patients with a history of overt HE.

show abstract

The economic burden of disease-related undernutrition in selected chronic diseases

Cited by 19 publications

References 18 publications

The economic cost of hospital malnutrition in Europe; a narrative review

The economic cost of hospital malnutrition in Europe; a narrative review

A systematic review of the malnutrition prevalence in hospitalized hip fracture patients and its associated outcomes

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Contact Info

Product

Resources

About